Bingsen Zhou

Bingsen Zhou

Auto-generated profile, based on publicly available information

Bingsen Zhou

Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Cancer Research
Verified
Journal Article
Open access
PDF file
LXLijun Xue
Lijun Xue
BZBingsen Zhou
Bingsen Zhou
XLXiyong Liu
Xiyong Liu
YHYvonne Heung
Yvonne Heung
JCJennifer Chau
Jennifer Chau
YYYun Yen
Yun Yen
P53R2, which is one of the two known ribonucleotide reductase small subunits (the other being M2), is suggested to play an important role in supplying deoxynucleotide triphosphates (dNTP) for DNA repair during the G1 or G2 phase of the cell cycle. The ability of p53R2 to supply dNTPs for repairing DNA damages requires the presence of a functional p53 tumor suppressor. Here, we report in vivo physical interaction and colocalization of p53R2 and p21 before DNA damage. Mammalian two-hybrid assay further indicates that the amino acids 1 to 113 of p53R2 are critical for interacting with the NH2-terminal region (amino acids 1–93) of p21. The binding between p21 and p53R2 decreases inside the nucleus in response to UV, the time point of which corresponds to the increased binding of p21 with cyclin-dependent kinase-2 (Cdk2), and the decreased Cdk2 activity in the nucleus at G1. Interestingly, p53R2 dissociates from p21 but facilitates the accumulation of p21 in the nucleus in response to UV. On the other hand, the ribonucleotide reductase activity increases at the corresponding time in response to UV. These data suggest a new function of p53R2 of cooperating with p21 during DNA repair at G1 arrest. [Cancer Res 2007;67(1):16–21]

Verified
Journal Article
Open access
PDF file
Yunping QiuYunping Qiu
Yunping Qiu
BZBingsen Zhou
Bingsen Zhou
MSMingming Su
Mingming Su
SBSarah Baxter
Sarah Baxter
XZXiaojiao Zheng
Xiaojiao Zheng
WJWei Jia
Wei Jia
Breast cancer accounts for the largest number of newly diagnosed cases in female cancer patients. Although mammography is a powerful screening tool, about 20% of breast cancer cases cannot be detected by this method. New diagnostic biomarkers for breast cancer are necessary. Here, we used a mass spectrometry-based quantitative metabolomics method to analyze plasma samples from 55 breast cancer patients and 25 healthy controls. A number of 30 patients and 20 age-matched healthy controls were used as a training dataset to establish a diagnostic model and to identify potential biomarkers. The remaining samples were used as a validation dataset to evaluate the predictive accuracy for the established model. Distinct separation was obtained from an orthogonal partial least squares-discriminant analysis (OPLS-DA) model with good prediction accuracy. Based on this analysis, 39 differentiating metabolites were identified, including significantly lower levels of lysophosphatidylcholines and higher levels of sphingomyelins in the plasma samples obtained from breast cancer patients compared with healthy controls. Using logical regression, a diagnostic equation based on three metabolites (lysoPC a C16:0, PC ae C42:5 and PC aa C34:2) successfully differentiated breast cancer patients from healthy controls, with a sensitivity of 98.1% and a specificity of 96.0%.

1 March 2003
Verified
Journal Article
Closed access
LXLijun Xue
Lijun Xue
BZBingsen Zhou
Bingsen Zhou
XLXiyong Liu
Xiyong Liu
WQWeihua Qiu
Weihua Qiu
ZJZhongchu Jin
Zhongchu Jin
YYYun Yen
Yun Yen

1 May 2005 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
LZLijun Zhu
Lijun Zhu
GSGeorge Somlo
George Somlo
BZBingsen Zhou
Bingsen Zhou
JSJimin Shao
Jimin Shao
VBVictoria Bedell
Victoria Bedell
YYYun Yen
Yun Yen
The presence of t(4;14)(p16.3;q32.3) in multiple myeloma cells results in dysregulated expression of the fibroblast growth factor receptor 3 (FGFR3). FGFR3 acts as an oncogene to promote multiple myeloma cell proliferation and antiapoptosis. These encourage the clinical development of FGFR3-specific inhibitors. Three short hairpin RNAs (shRNA) targeting different sites of FGFR3 were selected and subsequently transfected into KMS-11, OPM-2, and NCI-H929 human myeloma cell lines, all of which are characterized by t(4;14) and FGFR3 over expression. The combination of these three shRNAs can effectively inhibit FGFR3 expression in all three cell lines. Sequential immunocytochemistry/fluorescence in situ hybridization was employed to validate that the shRNAs specifically inhibited FGFR3 expression in OPM-2 cells. Decreased expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) and myeloid cell leukemia sequence 1 (MCL1) proteins and increased staining of Annexin V–positive cells showed that inhibition of FGFR3 induces apoptosis. After confirming down-regulation of FGFR3 by real-time PCR, HU-133 plus 2.0 array was employed to compare the gene expression profile of shRNA-treated sample with that of the control. Besides the down-regulation of FGFR3, expression of the antiapoptotic genes CFLAR, BCL2, MCL1, and some members of NF-κB family decreased, whereas expression of the proapoptotic genes CYC, BID, CASP2, and CASP6 increased. Microarray results also revealed changes in genes previously implicated in multiple myeloma pathogenesis (RAS, RAF, IL-6R, and VEGF), as well as others (TLR4, KLF4, and GADD45A) not previously linked to multiple myeloma. Our observations indicate that shRNAs can specifically and effectively inhibit FGFR3 expression. This targeted approach may be worth testing in multiple myeloma patients with t(4;14) and FGFR3 overexpression in the future.

15 October 2003
Verified
Journal Article
Closed access
BZBingsen Zhou
Bingsen Zhou
XLXiyong Liu
Xiyong Liu
XMXueli Mo
Xueli Mo
LXLijun Xue
Lijun Xue
DDDana Darwish
Dana Darwish
YYYun Yen
Yun Yen

10 August 2002
Verified
Journal Article
Closed access
BZBingsen Zhou
Bingsen Zhou
SMShu Mi
Shu Mi
XMXueli Mo
Xueli Mo
JSJennifer Shih
Jennifer Shih
JTJeffery Tsai
Jeffery Tsai
YYYun Yen
Yun Yen